We are delighted in welcoming Prof Peter Edman as a new member of the Board of Directors of Mind the Byte. Since autumn last year, Edman has already been involved with the company as a member of its Advisory Board and has participated in the definition of the strategic goals for the upcoming years.
He has a PhD in Biochemistry and has extensive experience in research and development in the pharmaceutical industry, where he has held a number of senior positions within Orexo, Sobi, Biovitrum, Pharmacia, Astra and multinational corporation AstraZeneca.
Edman has also been Professor in Pharmaceutical Formulation and Adjunct Professor in Drug Delivery at the Faculty of Pharmacy of the Uppsala University (Sweden). He is now acting as an independent scientific advisor and board member to companies within the life science sector.
"Peter Edman brings a great depth and breadth of experience in scientific leadership and management capabilities to Mind the Byte. In addition, Peter's knowledge about small molecules and all the phases of drug development will be a great asset to the company," says Mind the Byte's CEO Alfons Nonell-Canals.
"I am really excited about joining Mind the Byte. I strongly believe in Mind the Byte's strategy and focused ambitions to become a strong, international company within the computational drug discovery field. I am confident that Mind the Byte will become a strong player in the global drug development market," says Peter Edman.
His appointment has been confirmed by the shareholders at the Annual General Meeting on June 29, 2017. In the same meeting, Dr Galí Drudis resignation as a board member was approved.